We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Proteon Therapeutics, which focuses on kidney and vascular diseases, has signed a definitive agreement to merge with rare and speciality disease drugs developer ArTara Therapeutics.